Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.49 |
| ▸ | PLA2G7 | Q13093 | 10/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176698 | 0.93 | MAPT (0.57) | UTS2RPLA2G7MAPTCACNA1BCACNA1H | |
| SCHEMBL6174293 | 0.83 | MAPT (0.62) | PLA2G7MAPTCACNA1BCACNA1HHSD11B1 | |
| SCHEMBL6176415 | 0.80 | MAPT (0.48) | UTS2RPLA2G7MAPTCACNA1BCACNA1H | |
| SCHEMBL6176466 | 0.78 | MAPT (0.47) | UTS2RPLA2G7MAPTGPR119CACNA1B | |
| SCHEMBL6176764 | 0.78 | MAPT (0.46) | UTS2RPLA2G7MAPTGPR119CACNA1B | |
| SCHEMBL6176624 | 0.77 | UTS2R (0.57) | UTS2RPLA2G7MAPTCACNA1BCACNA1H | |
| SCHEMBL6178234 | 0.74 | CACNA1B (0.54) | UTS2RMAPTCACNA1BCACNA1H | |
| SCHEMBL6174364 | 0.74 | CACNA1B (0.49) | UTS2RMAPTCACNA1BCACNA1H | |
| Hydrochloric Acid SCHEMBL6176770 | 0.74 | MAPT (0.59) | PLA2G7MAPTGPR119CACNA1BCACNA1H | |
| SCHEMBL6135391 | 0.73 | UTS2R (0.61) | UTS2RCACNA1BCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152893-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885PLA2G7 519/4885MAPT 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.